{"id":"W2056723407","doi":"10.1007/s10637-008-9143-2","title":"O-Mel-Inib: A Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma","year":2008,"lang":"fr","type":"article","venue":"Investigational New Drugs","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Mashhad University of Medical Sciences","keywords":"Medicine; Imatinib mesylate; Adverse effect; Phases of clinical research; Clinical trial; Melanoma; Internal medicine; Imatinib; Surgery; Oncology; Gastroenterology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005252209,0.0004901682,0.001081346,0.0003442171,0.0002349478,0.00001153272,0.0002184117,0.00027642,0.001036638],"category_scores_gemma":[0.0006864587,0.0004812645,0.0002580261,0.00054164,0.0009986092,0.0003561604,0.0001063518,0.0005087123,0.0003921689],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004343818,"about_ca_system_score_gemma":0.00345171,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005472891,"about_ca_topic_score_gemma":0.0005949424,"domain_scores_codex":[0.9961393,0.0004719385,0.001367217,0.0005956496,0.0007462634,0.0006795625],"domain_scores_gemma":[0.9974906,0.0006213827,0.0005780436,0.0004232242,0.0002068791,0.0006798489],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3001349,0.1175363,0.1585328,0.003161604,0.01456632,0.02343001,0.100574,0.002501862,0.009756983,0.07314406,0.06005787,0.1366033],"study_design_scores_gemma":[0.8785456,0.01848358,0.04605879,0.001976826,0.002543255,0.0006397219,0.0006138114,0.004631635,0.01430767,0.01157525,0.01950103,0.001122851],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819058,0.002838972,0.00003328679,0.009475622,0.002752718,0.00169574,0.0003745203,0.00003898699,0.0008843117],"genre_scores_gemma":[0.9728541,0.0002137809,0.01331571,0.001063033,0.001000658,0.0001184626,0.0007212272,0.00006042367,0.0106526],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5784107,"threshold_uncertainty_score":0.9998766,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04069337693991506,"score_gpt":0.3313887372190749,"score_spread":0.2906953602791599,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}